Seth Ablordeppey, Ph.D.

Eminent Scholar Chair and Professor Pharmaceutical Sciences
LOCATION: East Wing Pharmacy Building Suite # L1-230
EMAIL: seth.ablordeppey@famu.edu
PHONE: 850-599-3834

EDUCATION

Seth Ablordeppey, Ph.D., serves as a professor, Basic Pharmaceutical Sciences, and Eminent Scholar Chair and Fulbright Scholar, Biomedical Sciences.

Dr. Ablordeppey joined FAMU as an assistant professor in 1993, having served as a postdoctoral fellow at the Medical College of Virginia in Richmond, Virginia. His research involves computer-aided design, synthesis, and evaluation of compounds targeting specific CNS receptors; natural products as sources of the identification of new scaffolds for drug discovery and development; formulation of structure-activity relationships; 3-D models in drug design; and development of novel orally effective anti-infective agents against opportunistic infections and emerging infectious diseases.

Administratively, he has served for 11 years as Division Director of the Basic Pharmaceutical Sciences and became the Interim Dean of the College of Pharmacy and Pharmaceutical Sciences from Feb 2011 to June 2012 and May 2017 to October 2018.

Dr. Ablordeppey has several honors and recognitions. He was one of three who established the Pharmacy school at the University of Lagos in Nigeria in 1981. He was awarded the Florida Education Fund’s 2016 William R. Jones Outstanding Mentor for outstanding contribution to the McKnight Doctoral Fellowship Program; Joseph Sam Distinguished Alumnus Award in recognition of outstanding contribution in the field of medicinal chemistry in 2014; FAMU Research Excellence Award in 2010; Researcher of the Year, COPPS, 2008-2009; Advanced FAMU Teacher of the Year, 2002-2003; COPPS Teacher of the Year, 2001-2002; and University-wide Teacher of the Year, 1999-2000. He is also the recipient of the U.S. State Department Award as a Fulbright Fellow to Kwame Nkrumah University of Science and Technology in 2010-2011. Through this service to the people of Ghana, he established a collaborative relationship with the Kwame Nkrumah University of Science and Technology to develop natural products as new drugs.

Dr. Ablordeppey is a member of several Review Panels including, Loan Repayment Program, 2011 to date; and NIH Cancer Drug Discovery for Therapeutics Study Section, 2013, to date. Additionally, he served as president-elect, president, and member of the Board of the Emergency Care Help Organization (ECHO) in Tallahassee, Florida, and has led several Medical Missions to the people of Southern Ghana.

He has served as a research mentor to both undergraduate and graduate students, coordinated and mentored high school students through the American Chemical Society’s Project SEED program, and as of May 2019, he has produced 13 Ph.D. graduates in the pharmaceutical/biomedical sciences. He has also mentored numerous postdoctoral fellows and technicians.

Dr. Ablordeppey has received numerous grants over the years from various agencies and currently has over 60 published peer-reviewed articles and book chapters, over 60 presentations in various settings around the world, and has been awarded four patents and four provisional letters. In April 2019, Dr. Ablordeppey was selected as a fellow of the National Academy of Inventors. He currently holds several patents and has signed a licensing agreement for the development of novel antipsychotic agents.

Areas of Expertise
  • Drug discovery and drug development using natural products.

Research Interest
  • Developing new drugs for CNS diseases (including schizophrenia and depression) and emerging opportunistic infections such as MRSA.

Selective Publications
  • Bricker, B. A, Peprah, K.; Kang, H. J.; Ablordeppey, S. Y. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019, 179, 55-62.

  • Onyameh, E. K.; Bricker, B.; Ofori, E.; Ablordeppey, S. Y. Enantioseparation of 5-chloro-2-(2-(3,4-dihydro-isoquinoline-2(1H)-yl)ethyl)-2-methyl-2,3-dihydro-1H-inden-1-one (SYA 40247), a high affinity 5-HT7 receptor ligand, by HPLC-PDA using amylose tris-(3, 5- dimethylphenylcarbamate) as a chiral stationary phase. Biomed Chromatogr. 2019, 33 (9), e4565.

  • Asong, G.; Zhu, X.Y.; Bricker, B.; Andey, T.; Amissah, F.; Lamango, N.; Ablordeppey, S.Y. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019, 27(12):2629-2636

  • Al-Ghanim, L.; Zhu, X.Y.; Asong, G.; Ablordeppey, S. Y. SYA 013 analogs as moderately selective sigma-2 (σ2) ligands: Structure-affinity relationship studies. Bioorg Med Chem. 2019, 27(12):2421-2426